Previous close | 5.80 |
Open | 5.65 |
Bid | 5.55 x N/A |
Ask | 5.90 x N/A |
Day's range | 5.65 - 5.70 |
52-week range | 3.62 - 6.05 |
Volume | |
Avg. volume | 5 |
Market cap | 4.974B |
Beta (5Y monthly) | 0.48 |
PE ratio (TTM) | 18.39 |
EPS (TTM) | 0.31 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (AK104-302/COMPASSION-15) were released presented in the form of oral presentation at the 2024 American Association for Cancer Research (AACR).
Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS<1%) non-small cell lung cancer (NSCLC) (NCT05990127).
Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody(cadonilimab)combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had been published in the official journal of the American Association for Cancer Research (AACR), Clinical Cancer Research, with an impact factor of 11.5.